SCHEMBL682803

SCHEMBL682803

Cn1c(=O)c2c(ncn2CC(O)CN2CCN(Cc3ccc(Cl)cc3Cl)CC2)n(C)c1=O

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.57
LMNA P02545 5/20 0.57
RXFP1 Q9HBX9 4/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 1/20 0.56
POLB P06746 3/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
MAPK1 P28482 1/20 0.52
HTT P42858 2/20 0.50
UBE2N P61088 2/20 0.50
GLA P06280 1/20 0.50
MAOB P27338 2/20 0.49
ADORA2A P29274 1/20 0.49
GAA P10253 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
ADORA1 P30542 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684353 0.97 SMN1; SMN2 (0.54) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL683588 0.89 ALDH1A1 (0.57) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL683975 0.88 LMNA (0.65) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL683589 0.86 ALDH1A1 (0.54) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL684003 0.85 SMN1; SMN2 (0.68) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL682806 0.85 LMNA (0.62) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL684337 0.84 SMN1; SMN2 (0.68) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL684000 0.83 SMN1; SMN2 (0.65) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1
SCHEMBL683981 0.83 TP53 (0.54) SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB
SCHEMBL14181820 0.83 MAPK1 (0.68) SMN1; SMN2LMNARXFP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF SMN1; SMN2 907/4885LMNA 2155/4885RXFP1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.